Bristol Rx Expansion Plans Include Biologics Manufacturing
Executive Summary
Bristol plans to expand into biologics development and manufacturing as part of its "external development" plans for the pharmaceutical division following the divestments of Clairol and Zimmer.
You may also be interested in...
Roche Tries Genentech Formula In Japan: Chugai Deal Follows 1990 Model
Roche will have "opt-in" rights on Chugai's Phase II rheumatoid arthritis agent in the U.S. as part of the merger agreement between the two firms
Roche Tries Genentech Formula In Japan: Chugai Deal Follows 1990 Model
Roche will have "opt-in" rights on Chugai's Phase II rheumatoid arthritis agent in the U.S. as part of the merger agreement between the two firms
Bristol BuSpar Share Halved By Generics; DuPont Deal Shows "Flexibility"
Bristol-Myers Squibb's BuSpar (buspirone) market share has been cut by more than half since the launch of generic products at the end of March.